INVENTIA-LIFE-SCIENCE
Inventia Life Science, a leading advanced cell model company, launched the Inventia Third Dimension Grant today. This grant will allow researchers studying fundamental biology or drug development to model and test hypotheses using 3D cell cultures. These advanced models enable scientists to test questions they’d be unable to answer using 2D cell cultures or animal models.
The Inventia Third Dimension Grant recipient will have Inventia’s RASTRUM benchtop device placed in their lab for three months. They’ll also receive all materials needed to generate at least six 96 or 384 well plates of 3D cell models.
RASTRUM is a high-throughput drop-on-demand bioprinter that can deposit cells and matrix components into common tissue culture microplates to form 3D cell cultures. Inventia opened a lab in Dublin last year to foster the use of advanced cell models throughout Europe.
“With 2D cell models or animal models, it’s impossible to conduct certain research that’s critical to the advancement of novel technologies,” says Daniel Vaughn, Inventia’s EU Commercial Director. “We expect the recipient of this grant to make great strides in their research — and to fully realise the opportunities that 3D models present for impactful breakthroughs — during the time they have the RASTRUM in their lab.”
Traditional 2D cell cultures and animal models lack the ability to accurately model human physiological interactions between tumours and their environment. With RASTRUM advanced cell models, scientists are able to design models that more precisely recreate those interactions allowing them to probe deeper into their field of study.
Application information
The Third Dimension Grant Program is open to academic and commercial laboratories not currently using the RASTRUM™ Platform in Europe. Applications are due before the 29th February 2024, and the recipient will be selected on 8th March 2024. Applicants should complete the submission form using the grant link.
About Inventia Life Science
Inventia is creating some of the most powerful tools for advanced biomedical discovery today. We build printers and formulate bioinks that, together, allow human cells to be printed in 3-dimensional structures and help forward-thinking pioneers in the fields of cancer research, drug discovery and medicine to create human tissue for research and therapy purposes. Our RASTRUM™ platform creates 3D cell cultures which imitate real human tissue in terms of structure and behaviour across a range of disease states. The physiological complexity of these cell cultures provides an environment in which world-class research and discovery can occur, right in the researcher’s own lab. Inventia Life Science was the vision of Dr. Julio Ribeiro and was founded by him with Dr. Aidan O'Mahony, Dr. Cameron Ferris and Peter Arthur in 2013. It is headquartered in Sydney, Australia.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231205284641/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Maxion Announces Strategic Actions to Serve Growing Demand for Light Vehicle Aluminum Wheels in South America3.11.2025 23:38:00 CET | Press release
Includes Joint Venture through Polimetal to Increase Capacity in Argentina Iochpe-Maxion (B3: MYPK3) through its wheels business, Maxion Wheels, announced the strategic expansion of its light vehicle aluminum wheels business in South America with the redeployment of existing global assets to Brazil, and the acquisition of a 50.1% shareholding in Polimetal, a leading producer of aluminum wheels in Argentina. “Passenger car sales continue to rise across South America, with our wheels business, especially light vehicle aluminum wheels, continuing to gain share in Mercosur,” stated Pieter Klinkers, President and CEO of Iochpe-Maxion. “To address this growing market and corresponding aluminum wheel demand, Maxion Wheels is implementing three strategic initiatives. First is the utilization of our global operations, together with our domestic forces in Brazil, to support the immediate additional demand. Second is the redeployment of existing global assets to our two Brazilian light vehicle al
GigaDevice Highlights Breakthroughs Across AI, Power, and Consumer Applications at Embedded World 20253.11.2025 17:00:00 CET | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, will present its latest breakthroughs in AI-driven facial and voice recognition, power management, and consumer applications, at this year’s Embedded World North America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103394601/en/ This is the second running of EWNA, with the expo taking place in Anaheim, CA, from the 4th of November. GigaDevice’s technology will be on display at Booth #6085 throughout the three-day exhibition. Like its European sister show, the event brings together many of the leading developers and system architects from across the embedded electronics sector. GigaDevice's demonstrations will highlight the performance and versatility of its GD32 MCU family across several demanding applications: Edge AI Recognition Systems: GigaDevice will showcase facial and voice reco
Coulson Aviation Develops SafeFuel, the First Onboard Fuel Quality Assurance and Protection System3.11.2025 16:30:00 CET | Press release
Coulson Aviation (USA), the world’s largest aerial firefighting company and operator of the most advanced mixed fixed- and rotary-wing firefighting fleet, has developed SafeFuel, the aviation industry’s first onboard system designed to verify fuel quality and detect contamination during refueling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103342390/en/ Coulson SafeFuel is the world’s first patented onboard fuel-quality assurance and protection system. It continuously analyzes the product during refueling, detecting contamination or chemical degradation in real-time, preventing unsafe fuel from ever reaching the tanks. The innovation comes amid growing safety concerns following multiple fuel-related incidents in military and commercial aviation, and recent Navy aircraft accidents under investigation. Coulson Aviation’s aircraft often operate in remote environments around the world, where the risk of contaminated or of
Stefanini Group and Scopism Survey Reveals Rapid AI Adoption, Identifies Key Global Trends Shaping Service Integration and Management (SIAM)3.11.2025 15:42:00 CET | Press release
Launched today at the Scopism Service North Conference in Manchester, UK, the report finds that 85% of organizations now use AI in key SIAM processes, while also highlighting integration and data privacy roadblocks Stefanini Group, a global tech consulting company with strong expertise in digital transformation and artificial intelligence solutions, and Scopism, a global leader in Service Integration and Management (SIAM) best practices, today announced the release of the Global SIAM Survey 2025 White Paper. The eighth annual report, sponsored by Stefanini, was launched and presented by a panel at the Scopism Service North Conference in Manchester, UK, and provides unrivalled insights into SIAM adoption, maturity, and emerging trends worldwide. The survey continues to track the impact of artificial intelligence (AI) on SIAM models. Results show that while reported use of AI in SIAM models overall has remained stable, AI adoption within specific areas, such as incident management, has i
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting3.11.2025 15:31:00 CET | Press release
INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated data in essential thrombocythemia (ET) and translational data demonstrating disease modifying activity in both ET and MF. Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in combination with ruxolitinib in GVHD Incyte to host an investor event and webcast highlighting the mutCALR data from the oral presentation at ASH on Sunday, December 7, 2025, from 11:00 a.m.-12:30 p.m. ET Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual Meeting, to be held December 6 – 9, 2025, in Orlando. "Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
